http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Hu, Xi,Sun, Jihong,Li, Fangyuan,Li, Ruiqing,Wu, Jiahe,He, Jie,Wang, Nan,Liu, Jianan,Wang, Shuaifei,Zhou, Fei,Sun, Xiaolian,Kim, Dokyoon,Hyeon, Taeghwan,Ling, Daishun American Chemical Society 2018 Nano letters Vol.18 No.2
<P>Although metallic nanomaterials with high X-ray attenuation coefficients have been widely used as X-ray computed tomography (CT) contrast agents, their intrinsically poor biodegradability requires them to be cleared from the body to avoid any potential toxicity. On the other hand, extremely small-sized nanomaterials with outstanding renal clearance properties are not much effective for tumor targeting because of their too rapid clearance in vivo. To overcome this dilemma, here we report on the hollow bismuth subcarbonate nanotubes (BNTs) assembled from renal-clearable ultrasmall bismuth subcarbonate nanoclusters for tumor-targeted imaging and chemoradiotherapy. The BNTs could be targeted to tumors with high efficiency and exhibit a high CT contrast effect. Moreover, simultaneous radio- and chemotherapy using drug-loaded BNTs could significantly suppress tumor volumes, highlighting their potential application in CT imaging-guided therapy. Importantly, the elongated nanotubes could be disassembled into isolated small nanoclusters in the acidic tumor microenvironment, accelerating the payload release and kidney excretion. Such body clearable CT contrast agent with high imaging performance and multiple therapeutic functions shall have a substantial potential for biomedical applications.</P>
Jie Chen,Chun-Xiang Tian,Miao Yu,Qing Lv,Nan-Sheng Cheng,Zu Wang,Xi Wu 한국유방암학회 2014 Journal of breast cancer Vol.17 No.1
Purpose: The aim of the study was to evaluate the efficacy andsafety of combining sorafenib with chemotherapy in patients withhuman epidermal growth factor receptor 2 (HER2)-negative advancedbreast cancer. Methods: MEDLINE, EMBASE, CochraneCentral Register of Controlled Trials, American Society for ClinicalOncology abstracts, and European Society for Medical Oncologyabstracts were searched. Randomized clinical trials that comparedthe efficacy and safety of sorafenib plus chemotherapy inpatients with HER2-negative advanced breast cancer with placeboplus chemotherapy were eligible. The endpoints were progression-free survival (PFS), overall survival (OS), time to progression(TTP), duration of response (DOR), overall response rate(ORR), clinical benefits, and adverse effects. The meta-analysiswas performed using Review Manager 5.2.6 (The Nordic CochraneCentre), and the fixed-effect model weighted by the Mantel-Haenszel method was used. When considerable heterogeneitywas found (p<0.1), further analysis (subgroup analysis, sensitivityanalysis, or random-effect model) was performed to identifythe potential cause. The results are expressed as hazard ratios orrisk ratios, with their corresponding 95% confidence intervals. Results: The final analysis included four trials comprising 844 patients. The results revealed longer PFS and TTP, and higher ORRand clinical benefit rates in patients receiving sorafenib combinedwith chemotherapy compared to those receiving chemotherapyand placebo. OS and DOR were similar in the two groups. Meanwhile,the incidence of some adverse effects, including hand-footskin reaction/hand-foot syndrome, diarrhea, rash, and hypertension,were significantly higher in the sorafenib arm. Conclusion:Sorafenib combined with chemotherapy may prolong PFS andTTP. This treatment was associated with manageable toxicities,but frequent dose interruptions and reductions were required.
( Bo Xu ),( Li Ming Dai ),( Jun Jun Li ),( Meng Deng ),( Hua Biao Miao ),( Jun Pei Zhou ),( Yue Lin Mu ),( Qian Wu ),( Xiang Hua Tang ),( Yun Juan Yang ),( Jun Mei Ding ),( Nan Yu Han ),( Zun Xi Huang 한국미생물 · 생명공학회 2016 Journal of microbiology and biotechnology Vol.26 No.1
Xylanases sourced from different bacteria have significantly different enzymatic properties. Therefore, studying xylanases from different bacteria is important to their applications in different fields. A potential xylanase degradation gene in Massilia was recently discovered through genomic sequencing. However, its xylanase activity remains unexplored. This paper is the first to report a xylanase (XynRBM26) belonging to the glycosyl hydrolase family (GH10) from the genus Massilia. The gene encodes a 383-residue polypeptide (XynRBM26) with the highest identity of 62% with the endoxylanase from uncultured bacterium BLR13. The XynRBM26 expressed in Escherichia coli BL21 is a monomer with a molecular mass of 45.0 kDa. According to enzymatic characteristic analysis, pH 5.5 is the most appropriate for XynRBM26, which could maintain more than 90% activity between pH 5.0 and 8.0. Moreover, XynRBM26 is stable at 37°C and could maintain at least 96% activity after being placed at 37°C for 1 h. This paper is the first to report that GH10 xylanase in an animal gastrointestinal tract (GIT) has salt tolerance, which could maintain 86% activity in 5 M NaCl. Under the optimum conditions, Km, Vmax, and kcat of XynRBM26 to beechwood xylan are 9.49 mg/ml, 65.79 μmol/min/mg, and 47.34 /sec, respectively. Considering that XynRBM26 comes from an animal GIT, this xylanase has potential application in feedstuff. Moreover, XynRBM26 is applicable to high-salt food and seafood processing, as well as other high-salt environmental biotechnological fields, because of its high catalytic activity in high-concentration NaCl.